Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, leifsmith, for the very substantial contribution to the otherwise minimal discussion on this board.
Seems like it would be fairly easy to structure a partnership with an Abbie Vie ( think Humira), to make it very profitable for Abbie, since they are most at risk from a successful MYMD-1.
Also, the arrangements being forged with The Arthritis Foundation and Bascom Palmer are good examples of cooperation where the partner has much to gain from that relationship. We would like to see more of these relationships where others see MyMD Pharmaceuticals as a valuable partner!
What do you think!
https://www.psychologytoday.com/us/blog/the-modern-brain/202207/serotonin-doesnt-cause-depression-so-what-does
So if it is not serotonin, maybe it is inflammation. The current phase 2 human study on Covid induced depression should tell us a lot.
GO MYMD-1!
A recent book called "Sickening" by John Abramson describes how healthcare in America is limited to treating symptoms in the most expensive way possible because of the financial dominance of the pharmaceutical industry. While MYMD's first two human studies do not challenge that dominance as there are no drugs treating healthy life extension or long Covid, a human study of MYMD-1 and its impact on rheumatoid arthritis would be of great concern. Add to that, the fact that MYMD-1 appears to treat over 100+ other diseases and medical conditions for which there are no current meds, and we have a situation where "big pharma" would like MyMD Pharmaceuticals to cease existing!!!!!
Today's news release looks more like a feeble attempt to give some support to the stock price by getting the company name before the public, rather than being a significant announcement of study progress. There are 4 cohorts at increasing dosages, and this is just a move to the next dosage level, there having been no problems at the initial level.
You said, "This is a straw in the wind, a good one. I'm paying attention."
This got me to pondering the BASCOM PALMER news release with more consideration than usual, and began wondering if maybe it is a model for future ventures where our partner pays the bill. This may be because I had been wondering if The Arthritis Foundation was going to contribute toward the expense of the MYMD-1 / rheumatoid arthritis phase 2 study.
Were we able to "collaborate" with The Arthritis Foundation in a similar manner as BASCO PALMER, and with The Diabetes Foundation, the groups seeking a cure for inflammatory diseases and inflammatory cancers, we would be going a long ways toward solving the finances problem!
More news from MYMD
https://ir.mymd.com/news-events/press-releases/detail/36/mymd-pharmaceuticals-to-collaborate-with-bascom-palmer-eye
Note that the relationship is fully funded by BASCOM EYE!
Here's the news!!!!!
https://seekingalpha.com/news/3855420-oramed-mymd-surge-on-plans-for-early-stage-oral-covid-vaccine-data-release-in-q3?utm_source=stck.pro&utm_medium=referral
My bad, see post 286 ! Seems like the Covid pill is alive and well!
"Looking for", or maybe "hoping for" would be more appropriate, MyMD Pharma to make a big splash in 2022's 2nd half beginning with the 5 to 6 minute video introducing MyMD Pharmaceuticals to the American public with presentations on numerous TV channels. Following up with early results of the Phase 2 post Covid depression study which indicates that MYMD-1 not only knocks down post Covid depression, but also appears to block "long Covid".
Follow this up with the publication in a highly respected medical journal with the results of the pre-clinical MYMD-1, healthy life extension rat study which highlights the survival rate of the strong and healthy "immortal rats". Along with this, provide the early results of the Phase 2 human study of over sixty-fivers diagnosed with sarcopenia who were treated with MYMD-1.
Next, have MyMD Pharma personnel brief The Arthritis Foundation on a planned Phase 2 study challenging subjects with Rhuematoid Arthritis with MYMD-1, then contact Iquvia to lead the study, hopefully financed in part by Arthritis Foundation funding.
Lastly, highlight the soon to begin Phase 2 studies challenging Hasimoto's Thyroiditis, Multiple Sclerosis, and Type 2 Diabetes with MYMD-1. If this doesn't light a fire under MYMD, then nothing will.
Looking like Oravax and its Covid 19 vaccine pill have dropped out of sight! There has been no word abought them since testing of the pill began in South Africa, and a presentation by Oramed in mid-May made no mention of the Oravax pill.
If anyone knows more about it please let us know.
Today's news release from MyMD is a major disappointment as they previously have said that preliminary results of the study were expected to be available by mid-year!
The New England Journal of Medicine sent me an email advertizing a new service they are offering, called "NEJM Catalyst (Innovations in Care Delivery)". On reading their description of the new service, my reaction was that it would be perfect for the coming introduction of MYMD-1.
Ironically, I had recently GOGGLED the most significant medical journals,and NEJM was right up there with the best, and had thought wouldn't it be great if it was the journal that was publishing the healthy life extension rat study.
B and B a tells us that the promised MYMD corporate profile will be broadcast widely soon. So we have this broadly broadcast corporate profile, the release of the preliminary results of the 2 human studies in progress, the publication of the healthy life extension rat study, and a new service from NEJM focussed on "Innovations In Care Delivery", all conviently adding up to a broad introduction by Jonnie and his team, of MYMD's focus of treating medical conditions and diseases rather than just treating symptons!
Perhaps that is why the WSJ website is still showing the one and only investor BUY signal with a price projection of $1,536.00 a share. It was posted last fall, and the price was predicted to be achieved within a year.
Pipe dream! Could be! Hope not!
Back in 2016 the "old" MYMD website stated that MYMD saw their mission as a company was to teach the medical industry and the pharmaceutical industry how to "treat disease" as opposed to just "treating the symptoms of disease".
I believe that that "teaching moment" is about to begin as the preliminary results from the first 2 human studies are revielled, and the publication in a suitable medical journal of the results of the preclinical lab rat study on "healthy aging" is published!
It remains to be seen if these results will make any difference in the price of MYMD, but I do believe that the healthy aging rat study will get a blizzard of attention as the public gets a vision of a drug in pill form that will deliver a longer and healthier lifespan!
Can anyone offer some insight as to why MYMD was up nearly 5.5% on nearly 110K shares on a day when the averages plummeted!
WHOA !!!!! THAT'S FANTASTIC NEWS IF IT'S TRUE !!!!! RAY'S COMPANY IS LOCATED IN BALTIMORE, JUST A SHORT DISTANCE FROM MyMD PHARMA'S HEADQUARTERS AND IS PROBABLY CLOSER TO WHAT'S GOING ON THERE THAN ANY OTHER OUTSIDER !!!!!
Johns Hopkins Magazine has posted the following article about inflammation being responsible for loss of smell with Covid 19.
https://hub.jhu.edu/2022/04/12/inflammation-causes-covid-19-loss-of-smell/?utm_source=Hub+subscribers&utm_campaign=9603a68f4a-EMAIL_CAMPAIGN_2022_04_12_04_30_COPY_01&utm_medium=email&utm_term=0_d8bf41c16e-9603a68f4a-71566960&mc_cid=9603a68f4a&mc_eid=aca893738c
I am assuming that this is the material that MYMD will be presenting at an upcoming Arthritis Foundation event, to be followed by an application for a Phase 2 study of MYMD-1 vs Rheumatoid Arthritis! I'm also assuming that The Arthritis Foundation will be providing some of the funding for the Phase 2 study.
Great contribution to the subject of healthy life extension, but unfortunately would leave the average reader, in my opinion, totally confused because of all the unfamiliar terms.
I much prefer the explanation that focusses on the fairly recent discovery that the immune system and the metabolic system do not operate totally independently, as has long been taught, but at times work together and have been given the "new science" name IMMUNOMETABOLISM. When working properly together you have homeostasis, as in a young, healthy mammal. When not working properly together you have a condition known as "immunobolic disregulation".
Turns out that MYMD-1 gently nudges "immunometabolic disregulation" towards "homeostasis", reducing or correcting the resulting medical condition or disease.
Thus, as we age and disregulation occurs more frequently, MYMD-1 taken daily is there to "gently nudge disregulation back toward homeostasis" leading to longer and healthier aging.
Accelerates the pace, but not the price. Looks like it's going to take some definite proof of benefit to move this incredible stock!
A quick reading of the Annual Report left me with a recollection of the following paragraph.
" Sales and Marketing
MyMD does not currently have sales and marketing infrastructure to support the launch of its products. MyMD intends to build such capabilities in North America prior to launch of MYMD-1. Outside of North America, MyMD may rely on licensing, co-sale and co-promotion agreements with strategic partners for commercialization of its products."
I had posted previously that I thought their best chance for success was to demonstrate MYMD-1's value through successful Phase 2 studies, then license them to appropriate international pharmaceutical companies in exchange for progress payments and royalties. The quoted paragraph above seems like a good alternative.
GREAT FIND !!!!! MUCH THANKS FOR SHARING.
"WUS UP". Consistent 3-day buying on moderate volume with no news !!!
A million shares short doesn't sound like much when they have 200 million shares outstanding!
Here is the link to Dr. Adam Kaplin's presentation on "Cheddar Innovates"
https://cheddar.com/media/this-anti-aging-drug-is-disrupting-a-600-billion-industry
Sarcopenia/Frailty study posted on St. Patrick's Day.
https://clinicaltrials.gov/ct2/show/NCT05283486
Interesting to note that Ray Blanco's "ST. Paul Research" is named after its location which is 808 St. Paul St., Baltimore, MD, a mere 7 minute drive to MYMD's Corporate address at 855 N. Wolfe St. in Baltimore.
A thousand "THANKS" for sharing as most of us do not have access to Ray's coverage of MYMD.
Have been hop[ng for release of the healthy aging mouse study. Thought maybe "immortal mice" would intrigue the media!
Today's news release describing MYMD-1's success in reducing TNFa in healthy subjects is an "in your face", "unabashed claim", of major accomplishment that drew a yawn from the media and Wall Street. Either they just don't understand its significance, or they just don't want to publicize it.
Anyone know if the 8.1% of shares recently reported were purchased directly from the company, and if so, how much money did AERG receive for the shares.
Most everything I follow is being crushed so AERG is nothing special!
On Dec. 14 Oramed announced it had selected its first candidate to receive the Oravax Covid 19 vaccine pill with the 2nd pill to be administered 3 weeks later, in a phase 1 trial of the pill.
Does anyone know how long it will take to acquire definitive results of the effectiveness of the pill with this 1st candidate.
https://finance.yahoo.com/news/oramed-subsidiary-oravax-announces-first-130000048.html
With MYMD trading in the $5.00 range at a time when its outlook appears to look awesome, we need to look elsewhere for the silver lining. That may be in the area of the relationships it has formed.
To begin with, MYMD's corporate office is located in a building owned by Johns Hopkins, which is located on the Johns Hopkins campus, and whose dedication includes nuturing small companies working on medical breakthroughs! We know from previous news releases that much of what we know about MYMD-1 was provided by Johns Hopkins researchers, and we know from a recent news release that Johns Hopkins is a leader in R and D research.
https://hub.jhu.edu/2021/02/09/nsf-research-development-funding-rankings-2019/
Next, we know that MYMD has apparently formed a cozy relationship with The Arthritis Foundation, evidenced 1st by its selection of MYMD's President, Chris Chapman, as its "Medical Honoree of 2021", and 2nd by the fact that following an MYMD presentation at the Arthritis Foundation in early 2022, MYMD will begin writing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis, hopefully financially supported by The Arthritis Foundation.
Additionally, the rheumatoid arthritis study will be undertaken with the assistance of IQVIA, a global company focussed on driving healthcare forward. Chris Chapman was hired by Quintiles, now known as IQVIA, in 1995 where he grew a division from no employees to 40 employees, including 8 physicians, before moving on in 2003. Jude Uzonwanne, a Director, was also an IQVIA employee at one point in his career.
Alison O'mahony, a Scientific Advisory Board member, is an employee of Eurofins Discovery, an international supporter of drug discovery. It was they, that determined that MYMD-1 was anti-prolific, anti-fibrotic, and performed as an JAK blocker equal to the 3 leading JAK blockers.
All in all MYMD has done an excellent job of developing support relationships that enhance its potential for success!
Which application will win the race. Sarcopenia, or rheumatoid arthritis, as it says in the last sentence of the announcement, " MyMD is in ongoing preparation with IQVIA for an Investigational New Drug (IND) and protocol for a Phase 2 study of MYMD-1 for rheumatoid arthritis in early 2022."
Actually I was extremely interested and am desperate to see it published as the major media might finally pick up the MYMD story based on the immortal mice!
Sorry leifsmith, I won't consider the chart science until it completes peer review and is published. Moreover, it needs to be proven of value to humans, not just rats. That would be science!
link to Barron"s- https://www.barrons.com/market-data/stocks/MYMD?mod=searchbar
He is seeing the same thing we are, but MYMD has no SCIENCE, just pre-clinical. We need to see some valid test results that support what MYMD is claiming in its patents!
"50 dollar stock in a few months". One investor has made a future price prediction on MYMD and it was $1536 by next Fall. See attached
"50 dollar stock in a few months". One investor has made a future price prediction on MYMD and it was $1536 by next Fall. See attached
Huge thanks, leif, for posting the link! I missed the original presentation and couldn't find the link. Looking for a boost from the mouse study publication results, or from news that the Oravax Covid vaccine pill is highly affective against Omicron!